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ABSTRACT 
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating 
relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its 
action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to 
enhanced apoptosis. Although the α subunit of hypoxia‑inducible factor (HIF)‑1 is not 
degraded with bortezomib treatment, the heterodimeric HIF‑1 fails to transactivate target 
genes. HIF‑1 and HIF‑2 are related hypoxia‑inducible transcription factors that are 
important for the survival of hypoxic tumor cells. The majority of reports have focused on the 
effects of bortezomib on the transcriptional activities of HIF‑1, but not HIF‑2. The present 
study investigated the effects of bortezomib on HIF‑2 activity in cancer cells with different 
levels of HIF‑1α and HIF‑2α subunits. HIF‑α subunit levels were detected using specific 
antibodies, while HIF transcriptional activities were evaluated using immunodetection, 
reverse transcription‑polymerase chain reaction and luciferase reporter assay. Bortezomib 
treatment was found to suppress the transcription and expression of CA9, a HIF‑1‑specific 
target gene; however, it had minimal effects on EPO and GLUT‑1, which are target genes of 
both HIF‑1 and HIF‑2. These data suggest that bortezomib attenuates the transcriptional 
activity only of HIF‑1, and not HIF‑2. This novel finding on the lack of an inhibitory effect 
of bortezomib on HIF‑2 transcriptional activity has implications for the improvement of 
design and treatment modalities of bortezomib and other PI drugs. 
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